Merus to Present at Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming investor conference participation.
The company's President and CEO, Bill Lundberg, M.D., will present at two major healthcare investment events:
- TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 9:10 a.m. ET
- Leerink Partners Global Healthcare Conference on Monday, March 10 at 11:20 a.m. ET
Webcasts of both presentations will be available live on the Investors page of the Merus website, with archived recordings accessible for a time after each event. The announcement comes as Merus continues to advance its portfolio of novel cancer therapeutics.
Merus N.V. (Nasdaq: MRUS), un'azienda oncologica in fase clinica che sviluppa anticorpi multispecifici innovativi e coniugati di farmaci anticorpali (Biclonics®, Triclonics® e ADClonics®), ha annunciato la sua partecipazione a prossimi eventi di conferenza per investitori.
Il presidente e CEO dell'azienda, Bill Lundberg, M.D., presenterà in due importanti eventi di investimento nel settore sanitario:
- TD Cowen 45a Conferenza Annuale sulla Salute martedì 4 marzo alle 9:10 a.m. ET
- Leerink Partners Conferenza Globale sulla Salute lunedì 10 marzo alle 11:20 a.m. ET
I webcast di entrambe le presentazioni saranno disponibili in diretta nella pagina Investitori del sito web di Merus, con registrazioni archiviate accessibili per un certo periodo dopo ogni evento. L'annuncio arriva mentre Merus continua a far progredire il suo portafoglio di nuove terapie contro il cancro.
Merus N.V. (Nasdaq: MRUS), una empresa oncológica en etapa clínica que desarrolla anticuerpos multispecíficos innovadores y conjugados de fármacos anticuerpos (Biclonics®, Triclonics® y ADClonics®), ha anunciado su participación en próximas conferencias para inversores.
El presidente y CEO de la empresa, Bill Lundberg, M.D., presentará en dos importantes eventos de inversión en el sector de la salud:
- Conferencia Anual de Salud de TD Cowen, 45ª edición, el martes 4 de marzo a las 9:10 a.m. ET
- Conferencia Global de Salud de Leerink Partners el lunes 10 de marzo a las 11:20 a.m. ET
Las transmisiones en vivo de ambas presentaciones estarán disponibles en la página de Inversores del sitio web de Merus, con grabaciones archivadas accesibles por un tiempo después de cada evento. El anuncio se produce mientras Merus continúa avanzando en su cartera de nuevas terapias contra el cáncer.
Merus N.V. (Nasdaq: MRUS)는 혁신적인 전장 다중 특이성 항체 및 항체 약물 접합체(Biclonics®, Triclonics® 및 ADClonics®)를 개발하는 임상 단계의 종양학 회사로, 다가오는 투자자 컨퍼런스 참여를 발표했습니다.
회사의 회장 겸 CEO인 Bill Lundberg, M.D.는 두 개의 주요 의료 투자 행사에서 발표할 예정입니다:
- TD Cowen 제45회 연례 건강 관리 컨퍼런스, 3월 4일 화요일 오전 9시 10분 ET
- Leerink Partners 글로벌 건강 관리 컨퍼런스, 3월 10일 월요일 오전 11시 20분 ET
두 발표의 웹캐스트는 Merus 웹사이트의 투자자 페이지에서 실시간으로 제공되며, 각 이벤트 후 일정 기간 동안 아카이브된 녹화도 이용할 수 있습니다. 이 발표는 Merus가 새로운 암 치료제 포트폴리오를 계속 발전시키는 가운데 이루어졌습니다.
Merus N.V. (Nasdaq: MRUS), une entreprise d'oncologie en phase clinique développant des anticorps multispecifiques innovants et des conjugués d'anticorps-médicaments (Biclonics®, Triclonics® et ADClonics®), a annoncé sa participation à des conférences pour investisseurs à venir.
Le président et CEO de l'entreprise, Bill Lundberg, M.D., présentera lors de deux grands événements d'investissement en santé :
- Conférence annuelle de santé TD Cowen, 45e édition, le mardi 4 mars à 9h10 ET
- Conférence mondiale de santé de Leerink Partners, le lundi 10 mars à 11h20 ET
Les webcasts des deux présentations seront disponibles en direct sur la page Investisseurs du site Web de Merus, avec des enregistrements archivés accessibles pendant un certain temps après chaque événement. L'annonce intervient alors que Merus continue de faire progresser son portefeuille de nouvelles thérapies contre le cancer.
Merus N.V. (Nasdaq: MRUS), ein klinisches Onkologieunternehmen, das innovative, vollwertige multispezifische Antikörper und Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, hat die Teilnahme an bevorstehenden Investorenkonferenzen angekündigt.
Der Präsident und CEO des Unternehmens, Bill Lundberg, M.D., wird auf zwei wichtigen Gesundheitsinvestitionsveranstaltungen präsentieren:
- TD Cowen 45. jährliche Gesundheitskonferenz am Dienstag, den 4. März um 9:10 Uhr ET
- Leerink Partners globale Gesundheitskonferenz am Montag, den 10. März um 11:20 Uhr ET
Webcasts beider Präsentationen werden live auf der Investoren-Seite der Merus-Website verfügbar sein, mit archivierten Aufzeichnungen, die nach jeder Veranstaltung für eine gewisse Zeit zugänglich sind. Die Ankündigung erfolgt, während Merus weiterhin sein Portfolio neuartiger Krebstherapien vorantreibt.
- Merus is actively engaging with investors through participation in prestigious healthcare conferences
- The company continues to advance its innovative oncology pipeline featuring proprietary antibody platforms
- Merus demonstrates transparency by providing public access to their investor presentations
- The company's leadership is directly involved in investor relations with the CEO presenting at conferences
- The press release doesn't provide specific updates on clinical progress or pipeline developments
- No financial information or business updates were included in the announcement
- The announcement lacks details about specific therapeutic candidates in development
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
- TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET
- Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.
Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.
FAQ
When will Merus (MRUS) present at the TD Cowen Annual Health Care Conference in 2025?
What conferences will Merus (MRUS) attend in March 2025?
How can investors access Merus (MRUS) conference presentations in March 2025?
What type of therapeutic products is Merus (MRUS) developing according to their February 2025 announcement?
Who will represent Merus (MRUS) at the March 2025 investor conferences?
